Navigation Links
Latent HIV infection focus of NIDA's 2010 Avant-Garde Award
Date:9/13/2010

The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, announced today that Dr. Eric M. Verdin of the J. David Gladstone Institutes in San Francisco, Calif., has been selected as the 2010 recipient of the NIDA Avant-Garde Award for HIV/AIDS Research for his proposal to study the mechanisms of latent HIV infection. NIDA's annual Avant-Garde award competition, now in its third year, is intended to stimulate high-impact research that may lead to groundbreaking opportunities for the prevention and treatment of HIV/AIDS in drug abusers. Awardees receive $500,000 per year for five years to support their research. Dr. Verdin is Senior Investigator and Associate Director of the Gladstone Institute of Virology and Immunology and Professor of Medicine at the University of California, San Francisco.

"Highly active antiretroviral therapy (HAART) has been very successful in managing HIV. However, these medications do not rid the body of the virus, and patients can become symptomatic and more infective if their treatment is interrupted," said NIDA Director Dr. Nora D. Volkow, who announced the award. "Dr. Verdin's innovative proposal seeks to identify the cellular proteins that control the latency process, which allows the virus to remain in a persistently dormant state, so that we can better understand how to completely eliminate the virus from the body."

The long-term persistence of HIV in a latent state in patients treated with HAART prevents the eradication of the disease, and forces patient to remain on HAART for their entire life. At this time, our understanding of how latent HIV infection occurs is basic. Dr. Verdin's project aims to develop a new single cell technology to examine how HIV latency is established, maintained, and how the virus becomes reactivated, in primary human lymphoid cells. By observing the fate of the virus in single cells, Dr. Verdin hopes to be able to devise novel strategies to eliminate latent HIV infection, or to restrict the latent pool to a size that can be controlled by the immune system.

Dr. Verdin was selected from 30 applicants whose proposals reflect diverse scientific disciplines and approaches to HIV/AIDS research. The Avant-Garde Awards are modeled after the NIH Pioneer Awards and are granted to scientists of exceptional creativity who propose high-impact research that will open new avenues for prevention and treatment of HIV/AIDS among drug abusers.

Drug abuse and its related behaviors, such as sharing drug injection equipment and/or engaging in risky sexual behavior while intoxicated, have been central to the spread of HIV/AIDS since the pandemic began more than 25 years ago. NIDA's HIV/AIDS research program supports a multidisciplinary portfolio that investigates the role of drug use and its related behaviors in the evolving dynamics of HIV/AIDS epidemiology, natural history, etiology, pathogenesis, treatment, and prevention. http://www.drugabuse.gov/AIDS.

For information about the Avant-Garde award for Innovative HIV/AIDS Research, please visit http://drugabuse.gov/avgp.html. Information about the 2011 Avant-Garde award will be posted on this site soon.


'/>"/>

Contact: Stephanie Older
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse
Source:Eurekalert

Related medicine news :

1. Burden of HIV/TB infections increasingly falling on Hispanic community
2. MSU researcher links potentially deadly infection, frequent cow exposure
3. Scientific community to set research agenda for infection prevention and control for next decade
4. 24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination
5. Heat Therapy Helps Treat U.S. Soldiers Infections
6. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
7. Flexible Floor-Cleaning Routine Helps School Prevent Spread of Infection
8. Study says therapeutics for trauma patients may not be effective due to an infection
9. Targeting blood vessels, immune system may offer way to stop infection-caused inflammation
10. Studies Show Significant Increases of C. Difficile Infections (CDI)
11. New superbug surpasses MRSA infection rates in community hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... human performance, is proud to announce that it has received 510(k) clearance from ... the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... BC (PRWEB) , ... April 25, 2017 , ... The ... from Richmond, BC, who live with dental fear and require sedation to receive dental ... at ease during various procedures, from hygienic cleanings to oral surgery, at their ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
(Date:4/25/2017)... Clara, CA (PRWEB) , ... April 25, 2017 ... ... announces the addition of predictive analytics to its patient care management module. Using ... compliance even before a patient has been initiated on continuous positive airway pressure ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology: